Developer docs
API playgroundTry for free, no card

Search company profiles

ArrePath

Full company profile

uuid0000pbm

Namestring
ArrePath
Legal namestring
ArrePath, Inc.
Websiteurl
arrepath.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

ArrePath is a Princeton University spin-out founded in 2022 that applies proprietary AI/ML and bacterial imaging technologies to discover novel anti-infective drugs addressing antimicrobial resistance. Its lead program, AP-001, is an oral LpxH inhibitor targeting multidrug-resistant Enterobacterales for outpatient urinary tract infections, with pre-development candidate nomination targeted for Q2 2026; a second program targets non-tuberculous mycobacterial (NTM) lung disease, and a third program (Project 3) extends the platform beyond infectious disease. Headquartered at 303A College Road East, Princeton, NJ, the company employs 11-50 people whose leadership team has contributed to the discovery, development, or approval of nine antibiotics.

The platform combines heterogeneous bioactivity rank-order modeling, scaffold-agnostic molecular representations with zero-shot generalization to new chemistry, ML-guided phenotypic high-throughput screening, and an indication-first parallel design workflow. Performance has been validated in a live discovery program: lead optimization completed in 17 months versus a typical 4-5 years, using 697 compounds versus 1,200-2,500 and an 8-person team versus 20-25. The zero-shot oral bioavailability model achieved AUC-ROC of approximately 0.72 versus 0.56 (public Random Forest) and 0.51 (public GNN), and the company improved oral bioavailability in its lead series from below 10% to over 80%. AP-001 demonstrates MIC90 ≤4 µg/mL across MDR, MBL, and CRE isolates with a low resistance frequency of approximately 1×10⁻⁹. The platform IP is held under exclusive license option from Princeton University based on founder Zemer Gitai's research.

ArrePath is pre-revenue and operates a B2B drug discovery and licensing model, seeking to out-license developed compounds and form co-development partnerships with pharmaceutical companies for clinical development and commercialization. Operations are funded through equity capital (a $20 million seed in March 2022 led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures, plus an undisclosed 2025 follow-on led by Boehringer Ingelheim Venture Fund with new investor AB Magnitude) and non-dilutive grants (CARB-X US$3.7M in April 2025; PACE £1M in November 2024). Pricing is not applicable at the current stage. Leadership includes CEO Kevin Krause (formerly CSO of AN2 Therapeutics), CSO Alita Miller (contributed to Xacduro and zoliflodacin at Entasis), CTO Kurt Thorn (former Senior Director of Data Science at Zymergen), and Chairman Diego Miralles (former CEO of Vividion and Laronde).

Short descriptiontext

ArrePath is an AI/ML-driven anti-infective drug discovery company spun out of Princeton University in 2022, developing novel oral antibiotics against drug-resistant infections including outpatient UTI and NTM lung disease for licensing to pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-infective drug discovery, machine learning platform, antibiotic pipeline development, phenotypic drug screening, antimicrobial resistance research
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-Infective Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

Developing novel antibiotic pipeline programs (outpatient UTI, NTM lung disease) intended for licensing to pharmaceutical partners or eventual commercialization. Pre-revenue stage company.

2Non-Dilutive Funding (Grants)
TypeProfessional Services
Description

Receiving grant funding from CARB-X ($3.7M) and PACE (£1M) to advance lead optimization programs. These funds support R&D without equity dilution.

arrepath.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ArrePath operates an AI/ML drug discovery platform that combines heterogeneous bioactivity data modeling, scaffold-agnostic molecular representations, indication-first parallel design, ML-guided phenotypic high-throughput screening, oral bioavailability prediction, and imaging-based mechanism-of-action prediction to discover novel anti-infective small molecules. The platform currently supports an internal pipeline of antibiotic programs intended for out-licensing or co-development with larger pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Lead optimization completed in 17 months vs typical 4-5 years, with 697 compounds vs typical 1,200-2,500, using 8-person team vs typical 20-25
+4 more records
Product overview1 text field

ArrePath operates as an AI-driven drug discovery company with a unified platform approach. Their core offering is a proprietary machine learning platform that combines heterogeneous bioactivity data processing, phenotypic imaging, and indication-first drug design to discover novel anti-infectives. The company applies this platform across a differentiated pipeline including: AP-001 (Project 1), an oral LpxH inhibitor for outpatient UTI currently in late lead optimization; Project 2 targeting NTM lung disease and tuberculosis; and Project 3 extending into non-infectious disease therapeutic areas. The platform's modular design enables cross-scaffold, cross-assay rank-order training that generalizes to new chemistry where conventional approaches and public models fail.

Product and service3 records
1AP-001 (Outpatient UTI Program)
CategoryAntibiotic Pipeline Program
Description

Novel oral small molecule LpxH inhibitor for outpatient urinary tract infections caused by multidrug-resistant Enterobacterales and carbapenem-resistant Enterobacterales (CRE), with potential for both oral and IV administration. Intended for out-licensing or co-development with pharmaceutical partners.

2NTM Lung Disease Program
CategoryAntibiotic Pipeline Program
Description

Novel oral compound classes targeting non-tuberculous mycobacteria including M. abscessus and M. avium complex (MAC), as well as tuberculosis, intended for out-licensing or co-development with pharmaceutical partners.

3Non-Infectious Disease Discovery Program
CategoryDrug Discovery Services
Description

Discovery program applying ArrePath's AI/ML platform and workflow to therapeutic areas beyond infectious disease, leveraging the generalizable data treatment, molecular representations, and indication-first design.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Scientific Advisory Board Members
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-11-18
Description

SAB includes Zemer Gitai (Founder, Princeton), Barbara Engelhardt (Stanford), Todd Black (TB Alliance), and appointed Connor Coley (MIT) and Paul Hergenrother (UIUC) in November 2022.

arrepath.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ArrePath is a spin-out from Princeton University with exclusive option to license platform technology IP from research published in Cell by Zemer Gitai. Founder Zemer Gitai is Edwin Grant Conklin Professor of Biology at Princeton.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Late-stage clinical biopharmaceutical company developing antibiotics for MDR bacterial infections, including oral and IV agents for UTIs and other serious infections. Comparable peer on modality (small-molecule antibiotics), target indications, and commercial-stage focus on the anti-infective market.

TypeBroad incumbent
Description

Public clinical-stage immunology company developing treatments for serious infectious diseases including hepatitis B, influenza, and HIV. Comparable on anti-infective focus and large-pharma partnership model, but operates at much larger scale and is not AI-platform-led.

TypeEmerging player
Description

AI-driven small molecule drug discovery company using structure-based deep learning for hit identification across multiple therapeutic areas. Comparable as an AI/ML platform for small molecule discovery, with overlapping technology approach but broader therapeutic focus and different target product profile.

TypeDirect peer
Description

Anti-infective drug developer acquired by Innoviva in 2022; focused on serious bacterial infections including Xacduro (sulbactam-durlobactam) for Acinetobacter. ArrePath's CSO Alita Miller was SVP of Biology at Entasis and contributed to Xacduro and zoliflodacin, making it a closely comparable anti-infective peer.

TypeBroad incumbent
Description

AI/ML-driven drug discovery company applying machine learning to biology across multiple therapeutic areas including neuroscience and metabolic disease. Comparable on platform-driven AI drug discovery approach, but broader in scope and not focused on anti-infectives.

TypeDirect peer
Description

Anti-infective developer focused on NTM (non-tuberculous mycobacterial) lung disease with epetraborole. ArrePath's CEO Kevin Krause was Chief Strategy Officer at AN2 leading its NTM program — directly overlapping on target indication, and ArrePath's Project 2 also targets NTM lung disease.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel classes of antibiotics targeting MDR Gram-negative bacteria. Comparable peer on modality, indication (MDR Gram-negative infections), and stage of development, with similar out-licensing and partnership-driven commercialization approach.

TypeDirect peer
Description

Anti-infective company developing oral antibiotics for complicated urinary tract infections (cUTI) and other multi-drug resistant infections. Directly comparable to ArrePath's lead AP-001 program in terms of indication (UTI), modality (oral antibiotic), and target patient population (MDR/Enterobacterales).

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Comparable on the AI/ML drug discovery platform paradigm, but operates at vastly larger scale and across broader indications rather than specializing in anti-infectives.

TypeDirect peer
Description

Private clinical-stage biopharmaceutical company developing novel antibiotics to combat MDR Gram-negative infections and difficult-to-treat bacterial pathogens. Closely comparable peer on modality (novel small molecule antibiotics), target pathogens (MDR Enterobacterales), and out-licensing-driven commercialization model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ArrePath

Anti-Infective Drug Discoveryarrepath.com

ArrePath is an AI/ML-driven anti-infective drug discovery company spun out of Princeton University in 2022, developing novel oral antibiotics against drug-resistant infections including outpatient UTI and NTM lung disease for licensing to pharmaceutical partners.

What ArrePath does

ArrePath is a Princeton University spin-out founded in 2022 that applies proprietary AI/ML and bacterial imaging technologies to discover novel anti-infective drugs addressing antimicrobial resistance. Its lead program, AP-001, is an oral LpxH inhibitor targeting multidrug-resistant Enterobacterales for outpatient urinary tract infections, with pre-development candidate nomination targeted for Q2 2026; a second program targets non-tuberculous mycobacterial (NTM) lung disease, and a third program (Project 3) extends the platform beyond infectious disease. Headquartered at 303A College Road East, Princeton, NJ, the company employs 11-50 people whose leadership team has contributed to the discovery, development, or approval of nine antibiotics.

The platform combines heterogeneous bioactivity rank-order modeling, scaffold-agnostic molecular representations with zero-shot generalization to new chemistry, ML-guided phenotypic high-throughput screening, and an indication-first parallel design workflow. Performance has been validated in a live discovery program: lead optimization completed in 17 months versus a typical 4-5 years, using 697 compounds versus 1,200-2,500 and an 8-person team versus 20-25. The zero-shot oral bioavailability model achieved AUC-ROC of approximately 0.72 versus 0.56 (public Random Forest) and 0.51 (public GNN), and the company improved oral bioavailability in its lead series from below 10% to over 80%. AP-001 demonstrates MIC90 ≤4 µg/mL across MDR, MBL, and CRE isolates with a low resistance frequency of approximately 1×10⁻⁹. The platform IP is held under exclusive license option from Princeton University based on founder Zemer Gitai's research.

ArrePath is pre-revenue and operates a B2B drug discovery and licensing model, seeking to out-license developed compounds and form co-development partnerships with pharmaceutical companies for clinical development and commercialization. Operations are funded through equity capital (a $20 million seed in March 2022 led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures, plus an undisclosed 2025 follow-on led by Boehringer Ingelheim Venture Fund with new investor AB Magnitude) and non-dilutive grants (CARB-X US$3.7M in April 2025; PACE £1M in November 2024). Pricing is not applicable at the current stage. Leadership includes CEO Kevin Krause (formerly CSO of AN2 Therapeutics), CSO Alita Miller (contributed to Xacduro and zoliflodacin at Entasis), CTO Kurt Thorn (former Senior Director of Data Science at Zymergen), and Chairman Diego Miralles (former CEO of Vividion and Laronde).

ArrePath firmographics

Firmographics
Name
ArrePath
Legal name
ArrePath, Inc.
Website
https://arrepath.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
ArrePath is an AI/ML-driven anti-infective drug discovery company spun out of Princeton University in 2022, developing novel oral antibiotics against drug-resistant infections including outpatient UTI and NTM lung disease for licensing to pharmaceutical partners.
Ownership category
akta.pro rank

ArrePath industry classification

Industry
Product category
Anti-Infective Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Anti-infective drug discovery
  • Machine learning platform
  • Antibiotic pipeline development
  • Phenotypic drug screening
  • Antimicrobial resistance research

Where ArrePath is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ArrePath business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pipeline Development and Licensing: Developing novel antibiotic pipeline programs (outpatient UTI, NTM lung disease) intended for licensing to pharmaceutical partners or eventual commercialization. Pre-revenue stage company.
  2. Non-Dilutive Funding (Grants): Receiving grant funding from CARB-X ($3.7M) and PACE (£1M) to advance lead optimization programs. These funds support R&D without equity dilution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ArrePath product offering

Product offering

Core offering

ArrePath operates an AI/ML drug discovery platform that combines heterogeneous bioactivity data modeling, scaffold-agnostic molecular representations, indication-first parallel design, ML-guided phenotypic high-throughput screening, oral bioavailability prediction, and imaging-based mechanism-of-action prediction to discover novel anti-infective small molecules. The platform currently supports an internal pipeline of antibiotic programs intended for out-licensing or co-development with larger pharmaceutical partners.

Product overview

ArrePath operates as an AI-driven drug discovery company with a unified platform approach. Their core offering is a proprietary machine learning platform that combines heterogeneous bioactivity data processing, phenotypic imaging, and indication-first drug design to discover novel anti-infectives. The company applies this platform across a differentiated pipeline including: AP-001 (Project 1), an oral LpxH inhibitor for outpatient UTI currently in late lead optimization; Project 2 targeting NTM lung disease and tuberculosis; and Project 3 extending into non-infectious disease therapeutic areas. The platform's modular design enables cross-scaffold, cross-assay rank-order training that generalizes to new chemistry where conventional approaches and public models fail.

Differentiator

Problem solved

Functional benefit

Products and services

  • AP-001 (Outpatient UTI Program) Novel oral small molecule LpxH inhibitor for outpatient urinary tract infections caused by multidrug-resistant Enterobacterales and carbapenem-resistant Enterobacterales (CRE), with potential for both oral and IV administration. Intended for out-licensing or co-development with pharmaceutical partners.
  • NTM Lung Disease Program Novel oral compound classes targeting non-tuberculous mycobacteria including M. abscessus and M. avium complex (MAC), as well as tuberculosis, intended for out-licensing or co-development with pharmaceutical partners.
  • Non-Infectious Disease Discovery Program Discovery program applying ArrePath's AI/ML platform and workflow to therapeutic areas beyond infectious disease, leveraging the generalizable data treatment, molecular representations, and indication-first design.

Quantifiable outcome

  • Lead optimization completed in 17 months vs typical 4-5 years, with 697 compounds vs typical 1,200-2,500, using 8-person team vs typical 20-25
  • +4 more outcomes

Companies that use ArrePath

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

ArrePath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

ArrePath partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • Scientific Advisory Board MemberssupportingStrategic or Co-development Partner · 18 November 2022SAB includes Zemer Gitai (Founder, Princeton), Barbara Engelhardt (Stanford), Todd Black (TB Alliance), and appointed Connor Coley (MIT) and Paul Hergenrother (UIUC) in November 2022.
  • Princeton UniversitycoreStrategic or Co-development PartnerArrePath is a spin-out from Princeton University with exclusive option to license platform technology IP from research published in Cell by Zemer Gitai. Founder Zemer Gitai is Edwin Grant Conklin Professor of Biology at Princeton.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

ArrePath competitors and assessment

Company assessment

Direct peers

  • Spero Therapeutics: Late-stage clinical biopharmaceutical company developing antibiotics for MDR bacterial infections, including oral and IV agents for UTIs and other serious infections. Comparable peer on modality (small-molecule antibiotics), target indications, and commercial-stage focus on the anti-infective market.
  • Entasis Therapeutics: Anti-infective drug developer acquired by Innoviva in 2022; focused on serious bacterial infections including Xacduro (sulbactam-durlobactam) for Acinetobacter. ArrePath's CSO Alita Miller was SVP of Biology at Entasis and contributed to Xacduro and zoliflodacin, making it a closely comparable anti-infective peer.
  • AN2 Therapeutics: Anti-infective developer focused on NTM (non-tuberculous mycobacterial) lung disease with epetraborole. ArrePath's CEO Kevin Krause was Chief Strategy Officer at AN2 leading its NTM program — directly overlapping on target indication, and ArrePath's Project 2 also targets NTM lung disease.
  • Bugworks Research: Clinical-stage biopharmaceutical company developing novel classes of antibiotics targeting MDR Gram-negative bacteria. Comparable peer on modality, indication (MDR Gram-negative infections), and stage of development, with similar out-licensing and partnership-driven commercialization approach.
  • Iterum Therapeutics: Anti-infective company developing oral antibiotics for complicated urinary tract infections (cUTI) and other multi-drug resistant infections. Directly comparable to ArrePath's lead AP-001 program in terms of indication (UTI), modality (oral antibiotic), and target patient population (MDR/Enterobacterales).
  • VenatoRx Pharmaceuticals: Private clinical-stage biopharmaceutical company developing novel antibiotics to combat MDR Gram-negative infections and difficult-to-treat bacterial pathogens. Closely comparable peer on modality (novel small molecule antibiotics), target pathogens (MDR Enterobacterales), and out-licensing-driven commercialization model.

Broad incumbents

  • Vir Biotechnology: Public clinical-stage immunology company developing treatments for serious infectious diseases including hepatitis B, influenza, and HIV. Comparable on anti-infective focus and large-pharma partnership model, but operates at much larger scale and is not AI-platform-led.
  • Insitro: AI/ML-driven drug discovery company applying machine learning to biology across multiple therapeutic areas including neuroscience and metabolic disease. Comparable on platform-driven AI drug discovery approach, but broader in scope and not focused on anti-infectives.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Comparable on the AI/ML drug discovery platform paradigm, but operates at vastly larger scale and across broader indications rather than specializing in anti-infectives.

Emerging players

  • Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning for hit identification across multiple therapeutic areas. Comparable as an AI/ML platform for small molecule discovery, with overlapping technology approach but broader therapeutic focus and different target product profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

ArrePath social profiles

Digital presence

ArrePath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ArrePath leadership team

Management profile

Number of profiles

Profiles5 records

ArrePath funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ArrePath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ArrePath

What does ArrePath do?

ArrePath operates an AI/ML drug discovery platform that combines heterogeneous bioactivity data modeling, scaffold-agnostic molecular representations, indication-first parallel design, ML-guided phenotypic high-throughput screening, oral bioavailability prediction, and imaging-based mechanism-of-action prediction to discover novel anti-infective small molecules. The platform currently supports an internal pipeline of antibiotic programs intended for out-licensing or co-development with larger pharmaceutical partners.

Is ArrePath a public or private company?

ArrePath is a private company. It is classified as venture growth investor backed and is currently operating.

When was ArrePath founded?

ArrePath was founded in 2022. It employs 11 to 50 people.

Where is ArrePath based?

ArrePath is headquartered in Princeton, United States, in the North America region.

How does ArrePath make money?

Two revenue lines are on record. Pipeline Development and Licensing is the primary driver. The others are non-Dilutive Funding (Grants).

Who are ArrePath's main competitors?

Direct peers on record are Spero Therapeutics, Entasis Therapeutics, AN2 Therapeutics, Bugworks Research, Iterum Therapeutics and VenatoRx Pharmaceuticals. Broad incumbents are Vir Biotechnology, Insitro and Recursion Pharmaceuticals. Atomwise is listed as an emerging player.

Does ArrePath have an API?

No public API is recorded for ArrePath.

What industry is ArrePath in?

ArrePath's product category is Anti-Infective Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizArrePath Closes Financing RoundArrePath raised a financing round led by Boehringer Ingelheim Venture Fund, with participation from existing and new investors, to advance its antibacterial drug discovery platform. The company will use the funds to progress its lead program AP-001 toward development candidate nomination and Phase 1 studies, and to expand compounds against non-tuberculous mycobacteria. It also appointed Diego Miralles as new chair of the board.ArrepathArrePath announces closing of their next financing round and appointment of new Board ChairArrePath raised its next financing round led by Boehringer Ingelheim Venture Fund, with participation from existing and new investors. The company will use the funds to advance its lead program AP-001 toward development candidate nomination and Phase 1 studies. Diego Miralles was appointed as new board chair.Business Wire BlogArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board ChairArrePath raised a financing round led by Boehringer Ingelheim Venture Fund, with new investor AB Magnitude, to advance its antibacterial drug discovery platform. The company also appointed Diego Miralles as board chair, citing his experience in biotech and pharmaceutical leadership.Business Wire BlogKevin Krause named President and CEO of ArrePathArrePath appointed Kevin Krause as President and CEO, bringing over 25 years of biotech experience. He previously served as Chief Strategy Officer at AN2 Therapeutics, leading its epetraborole Phase 2/3 NTM lung disease program. The company aims to advance its lead program to the clinic.Insight PartnersArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial ResistanceArrePath, a Princeton University spin-out developing machine learning-based anti-infective discovery, announced a $20 million seed round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures, with Viva BioInnovator, Arimed Capital, PTX Capital and Nor'easter Ventures participating. Dr. Lloyd Payne was named President and CEO. The company's platform, validated in a June 2020 Cell study, targets antimicrobial resistance.AiThorityArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial ResistanceArrePath, a Princeton University spin-out developing machine learning-based anti-infective discovery, announced $20 million in seed financing led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures, with Viva BioInnovator, Arimed Capital, PTX Capital and Nor'easter Ventures participating. Dr. Lloyd Payne was named President and CEO. The company has an exclusive option from Princeton to license related intellectual property.FinSMEsArrePath Raises $20M in Seed FinancingArrePath, a Princeton-based anti-infective drug discovery company, raised $20M in seed financing co-led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures. The funds will advance its machine learning-based platform for discovering new anti-infectives to combat antimicrobial resistance. Dr. Lloyd Payne was named President and CEO.Business Wire BlogArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial ResistanceArrePath raised $20 million in seed financing led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures. The company will use the funds to advance its machine learning-based platform for discovering new anti-infectives. Dr. Lloyd Payne was named President and CEO.Business Wire BlogArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial ResistanceArrePath, a Princeton University spin-out developing machine learning-based anti-infective discovery, announced a $20 million seed round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures, with Viva BioInnovator, Arimed Capital, PTX Capital and Nor'easter Ventures participating. Dr. Lloyd Payne was named President and CEO. The company's platform was validated in a June 2020 Cell paper.Venture Capital Access OnlineArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial ResistanceArrePath, a Princeton University spin-out focused on antimicrobial resistance, announced the closing of a $20 million seed financing round to advance its machine learning-based platform for discovering novel anti-infectives. The investment was co-led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures, with participation from Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures. Concurrently, Dr. Lloyd Payne was appointed President and CEO to lead the company's scientific and business strategy.